Press
Press
SyntekaBio Enters ‘Assetization Phase’ for AI Asset Program
SyntekaBio Enters ‘Assetization Phase’ for AI Asset Program
2026.01.22
SyntekaBio Enters ‘Assetization Phase’ for AI Asset Program
2026.01.22
Syntekabio wins SI deal from HYBE’s Weverse unit
2025.12.18
SyntekaBio Licenses Out Five AI-Designed Multispecific Antibodies to Panolos
2025.12.17
SyntekaBio, Panolos Sign MOU on Next-Gen Multispecific Antibodies
2025.12.06
SyntekaBio CEO, “No AI Drug Leader, a Chance for Us”
2025.11.26
Syntekabio Adopts GKE Hybrid Cloud for AI Drug Discovery
2025.11.07
Syntekabio, QIMRB report AI COPD drug progress; eyes first trial
2025.11.04
Syntekabio Unveils ‘Super-Gap’ Collaboration Model at APEC Event
2025.10.30
Syntekabio, Teams Up with MSKCC for Next Cancer Drug
2025.10.16
Syntekabio Begins Full-Scale Operation of AI-Driven Asset Program
2025.10.15
SyntekaBio Pushes AI Drug Discovery with 'DeepMatcher'
2025.09.27